The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.
about
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amountRapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotateSubacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.Prospective of ⁶⁸Ga-radiopharmaceutical development.Accuracy of 177Lu activity quantification in SPECT imaging: a phantom studyDual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate.Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging.68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Current status of theranostics in prostate cancer.Deadtime effects in quantification of 177Lu activity for radionuclide therapy.Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion.Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression.Splenic scintigraphy for further differentiation of unclear (68) Ga-DOTATOC-PET/CT findings: Strengths and limitations.68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.Accuracy and reproducibility of simplified QSPECT dosimetry for personalized Lu-octreotate PRRTThe difference between medicine and magic is that magicians know what they are doingIs there still a role for SPECT–CT in oncology in the PET–CT era?
P2860
Q33435622-06812991-3754-4D1A-9663-F1AE6AF65F33Q34157391-FF5CF29A-84EF-4C63-9740-1F826545E7B9Q35402008-C11EDFB3-AB8F-4A99-A569-B097B134B761Q35675498-6A0F0381-4DD1-4064-8712-74596DFFAAAAQ36143456-B8BAA021-B76C-4934-AC8F-735A99C1803DQ36516035-6B5148FC-01EF-42C0-BDB1-7D000AB0BD4DQ37435222-B94BB834-F2FE-4854-920C-8925E75E0702Q37568699-654A5122-8CAA-418D-92AC-4E21BE7DA58FQ38612027-69AEDD42-7027-483D-84D5-94135C426554Q38965866-8954505F-05DF-4032-9884-DE42C6B83088Q39066068-11ED1BD7-5C1E-4338-83E1-A322AEB5425DQ44670305-3D81B213-9488-4F99-9273-D7BD71A1AF6AQ45817194-471F718D-9E1B-4A3A-885C-ED27372FB786Q46225464-B36EC35A-A712-4AB4-B446-61D94BC1F700Q47241139-06857C53-723C-4C90-A088-C1FAD077C88FQ47721868-F2030E19-0B05-4E2E-A0D1-6A334D33D15FQ47988504-EFA6E159-EF48-4749-AA24-2996F7E3893EQ48342806-64DC229B-F073-473E-B114-5660DBE36C8BQ49451226-3EFA5F84-F5F7-441C-816B-6CE2B06E29A9Q50239890-DD74B167-E661-4CA0-94D4-EBFA457EBB65Q53125755-43FDE91B-2FDC-42AC-9C6B-D0DCA760881CQ57462267-50E80A23-E259-4A57-83FE-B1F131411C31Q57758762-7F06A889-9B20-4621-AE2B-B42859928FF4Q57758848-25754928-7655-48C3-A400-142698B9D729
P2860
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The tumour sink effect on the ...... receptor radionuclide therapy.
@en
The tumour sink effect on the ...... receptor radionuclide therapy.
@nl
type
label
The tumour sink effect on the ...... receptor radionuclide therapy.
@en
The tumour sink effect on the ...... receptor radionuclide therapy.
@nl
prefLabel
The tumour sink effect on the ...... receptor radionuclide therapy.
@en
The tumour sink effect on the ...... receptor radionuclide therapy.
@nl
P2860
P1476
The tumour sink effect on the ...... receptor radionuclide therapy
@en
P2093
Grace Kong
Michael S Hofman
P2860
P2888
P356
10.1007/S00259-011-1937-3
P577
2011-09-20T00:00:00Z